Important Rating: 10.05% to Target, Stifel Reaffirms “Hold” Rating for Medtronic (MDT) Stock

November 23, 2016 - By Linda Rogers

Important Rating: 10.05% to Target, Stifel Reaffirms

Medtronic (MDT) Rating

Stifel have a $81.0 PT on the stock. The PT suggests a potential upside of 10.05% from Medtronic (MDT)‘s previous stock close. This rating was disclosed in a research report on Wednesday, 23 November.

Medtronic PLC (NYSE:MDT) Ratings Coverage

Out of 2 analysts covering Medtronic (MDT), 2 rate it a “Buy”, 0 “Sell”, while 0 “Hold”. This means 100% are positive. $102.0 is the highest target while $95.0 is the lowest. The $98.50 average target is 33.63% above today’s ($73.71) stock price. Medtronic has been the topic of 2 analyst reports since August 23, 2016 according to StockzIntelligence Inc. Needham maintained the stock with “Buy” rating in Friday, August 26 report. Citigroup initiated the stock with “Buy” rating in Tuesday, August 23 report.

About 284,769 shares traded hands. Medtronic PLC (MDT) has declined 6.27% since April 21, 2016 and is downtrending. It has underperformed by 11.60% the S&P500.

Insitutional Activity: The institutional sentiment decreased to 0.73 in 2016 Q2. Its down 0.07, from 0.8 in 2016Q1. The ratio turned negative, as 60 funds sold all Medtronic PLC shares owned while 508 reduced positions. 93 funds bought stakes while 361 increased positions. They now own 1.03 billion shares or 1.89% more from 1.01 billion shares in 2016Q1.

Moreover, Strategic Services has 0.98% invested in Medtronic PLC (NYSE:MDT) for 55,480 shares. Segment Wealth Management Ltd last reported 7,897 shares in the company. Voya Inv Mngmt Ltd Com has invested 0.59% of its portfolio in Medtronic PLC (NYSE:MDT). The Switzerland-based Zurcher Kantonalbank (Zurich Cantonalbank) has invested 0.49% in Medtronic PLC (NYSE:MDT). Pathstone Family Office Lc reported 137 shares or 0.01% of all its holdings. Liberty Mutual Gp Asset Mgmt Inc has 0.3% invested in the company for 95,741 shares. Arrow holds 0.17% of its portfolio in Medtronic PLC (NYSE:MDT) for 7,459 shares. Vontobel Asset Management Inc holds 1.68% or 2.28 million shares in its portfolio. Guyasuta Advsr, a Pennsylvania-based fund reported 3,437 shares. Rosenbaum Jay D owns 15,225 shares or 0.19% of their US portfolio. Avalon Advisors Limited Liability Corporation holds 182,650 shares or 0.61% of its portfolio. Stillwater Cap Ltd Limited Liability Company, a Pennsylvania-based fund reported 112,839 shares. Sanders Ltd Co last reported 3.17% of its portfolio in the stock. Quantitative Invest Management Lc holds 0.58% or 143,500 shares in its portfolio. Moreover, Marshall Wace Ltd Liability Partnership has 0.82% invested in Medtronic PLC (NYSE:MDT) for 1.13M shares.

Medtronic Public Limited Company is a medical technology and services company. The company has a market cap of $101.86 billion. The Firm develops, makes and markets its medical devices and technologies to hospitals, physicians, clinicians and patients in approximately 160 countries. It has a 28.65 P/E ratio. The Firm operates in four divisions: Cardiac and Vascular Group, Minimally Invasive Technologies Group, Restorative Therapies Group and Diabetes Group.

According to Zacks Investment Research, “Medtronic is the world’s leading medical technology company, pioneering device-based therapies that restore health, extend life and alleviate pain. Primary products include those for bradycardia pacing, tachyarrhythmia management, atrial fibrillation management, among others. Medtronic operates its business in one reportable segment, that of manufacturing and selling device-based medical therapies. The company does business in more than 120 countries. The company’s product lines include cardiac rhythm management, neurological and spinal, vascular and cardiac surgery.”

MDT Company Profile

Medtronic Public Limited Company (Medtronic), incorporated on June 12, 2014, is a medical technology, services and solutions company. The Firm operates in four divisions: Cardiac and Vascular Group, Minimally Invasive Therapies Group, Restorative Therapies Group and Diabetes Group. The Cardiac and Vascular Group segment includes cardiac rhythm and heart failure, coronary and structural heart, and aortic and peripheral vascular. The Company’s Minimally Invasive Therapies Group segment includes surgical solutions, and patient monitoring and recovery. The Company’s Restorative Therapies Group segment includes spine, neuromodulation, surgical technologies and neurovascular. The Company’s Diabetes Group segment includes intensive insulin management, non-intensive diabetes therapies, and diabetes services and solutions. The Company’s subsidiaries include Medtronic, Inc. and HeartWare International, Inc.

More important recent Medtronic PLC (NYSE:MDT) news were published by: Reuters.com which released: “Medtronic sales disappoint, firm lowers forecast; shares fall” on November 22, 2016, also Investorplace.com published article titled: “Why Medtronic PLC (MDT), Dycom Industries, Inc. (DY) and Palo Alto Networks …”, Investorplace.com published: “Medtronic PLC (MDT) Stock Oozes Long-Term Strength” on November 02, 2016. More interesting news about Medtronic PLC (NYSE:MDT) was released by: Seekingalpha.com and their article: “Medtronic Experiences The Downside Of Size” with publication date: November 23, 2016.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

By

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our FREE daily email newsletter:


Recent Market News

>